MedTrace Logo

Study of NaQuinate in Healthy Volunteers

NCT04036617 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2019-07-30

No results posted yet for this study

Summary

Phase 1, randomised, double-blind, placebo-controlled study of NaQuinate in healthy subjects after single ascending oral (PO) doses and multiple ascending PO doses.

Conditions

Interventions

DRUG

NaQuinate

SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg

DRUG

Placebo

SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • Haoma Medica Limited

    lead INDUSTRY

Principal Investigators

  • Muna Albayaty, MBChB · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2019-12-31
Completion
2020-05-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04036617 on ClinicalTrials.gov